Paclitaxel and Carboplatin

Phase 3Small molecule

Paclitaxel and Carboplatin is one of 62 small molecule programs targeting Gynecologic Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gynecologic CancerNot yet recruiting

Vulvar CarcinomaRecruiting

Breast CancerRecruiting

Neoadjuvant ChemotherapyRecruiting

Gynecologic CancerPreclinical

Not yet recruiting

Vulvar CarcinomaPhase 2

Recruiting

Breast CancerPhase 3

Recruiting

Neoadjuvant ChemotherapyPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Phase 3

2 2

Adenocard

Astellas

Preclinical

2 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Tianeptine

Pfizer

Preclinical

1 5

Ablavar

LLantheus Medical Imaging

Preclinical

2 6

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 7

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 10

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

N/ANot yet recruiting

Gynecologic Cancer

NCT06977594

Q1 2029

Phase 2Recruiting

Vulvar Carcinoma

NCT04161664

Phase 2Recruiting

Vulvar Carcinoma

NCT04192253

Q3 2029

Phase 2Recruiting

Neoadjuvant Chemotherapy

NCT05905315

Q2 2034

Phase 2/3Recruiting

Breast Cancer

NCT03150576

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting·—·Phase 2/3·NCT03150576·780 enrolled

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02041338·200 enrolled

Vulvar Carcinoma2 trials

Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT04161664·12 enrolled

Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT04192253·51 enrolled

Lung Cancer2 trials

Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00035152·444 enrolled

dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.

Unknown status·KKarl Kölbeck·N/A·NCT02195336·20 enrolled

Ovarian Cancer1 trial

EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer

Completed·HHospices Civils de Lyon·Phase 2·NCT02001272·120 enrolled

Ovary Cancer1 trial

Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer

Unknown status·—·Phase 2/3·NCT02159820·500 enrolled

7 more indications

Esophageal Squamous Cell Carcinoma1 trial

A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT02570893·366 enrolled

Esophageal Cancer1 trial

A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

Completed·FFudan University·Phase 3·NCT02459457·321 enrolled

Malignant Neoplasm of Liver1 trial

Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography

Unknown status·SSun Yat-sen University·Phase 2·NCT01347424·40 enrolled

Neoadjuvant Chemotherapy1 trial

Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT05905315·98 enrolled

Gynecologic Cancer1 trial

Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

Not yet recruiting·SSeoul National University Hospital·N/A·NCT06977594·1,000 enrolled

Endometrial Cancer1 trial

A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer

Completed·FFan Ming·Phase 2·NCT01918124·80 enrolled

Effectiveness1 trial

Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

Unknown status·—·Phase 1/2·NCT02492503·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Paclitaxel and Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel and Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel and Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Paclitaxel and Carboplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Q3 2029

Q2 2034

Trials by Indication[1]

Breast Cancer2 trials

Vulvar Carcinoma2 trials

Lung Cancer2 trials

Ovarian Cancer1 trial

Ovary Cancer1 trial

Esophageal Squamous Cell Carcinoma1 trial

Esophageal Cancer1 trial

Malignant Neoplasm of Liver1 trial

Neoadjuvant Chemotherapy1 trial

Gynecologic Cancer1 trial

Endometrial Cancer1 trial

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News